Vaxcyte Inc. (PCVX): Price and Financial Metrics


Vaxcyte Inc. (PCVX): $26.18

0.16 (+0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PCVX Stock Price Chart Interactive Chart >

Price chart for PCVX

PCVX Price/Volume Stats

Current price $26.18 52-week high $55.93
Prev. close $26.02 52-week low $15.51
Day low $25.32 Volume 68,488
Day high $26.22 Avg. volume 288,750
50-day MA $24.46 Dividend yield N/A
200-day MA $23.77 Market Cap 1.37B

Vaxcyte Inc. (PCVX) Company Bio


Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.


PCVX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCVX Latest Social Stream


Loading social stream, please wait...

View Full PCVX Social Stream

Latest PCVX News From Around the Web

Below are the latest news stories about Vaxcyte Inc that investors may wish to consider to help them evaluate PCVX as an investment opportunity.

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.

Intrado Digital Media | September 21, 2021

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Annie Drapeau and Teri Loxam to its board of directors. In connection with these appointments, longtime board members Patrick Heron and Rob Hopfner have stepped down from the board.

Intrado Digital Media | September 20, 2021

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | September 13, 2021

Vaxcyte Inc (PCVX): Price Now Near $26.62; Daily Chart Shows An Uptrend on 50 Day Basis

This is the 2nd hour in a row pcvx has seen its price head up. The post Vaxcyte Inc (PCVX): Price Now Near $26.62; Daily Chart Shows An Uptrend on 50 Day Basis appeared first on ETF Daily News .

ETF Daily News | September 9, 2021

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Intrado Digital Media | August 11, 2021

Read More 'PCVX' Stories Here

PCVX Price Returns

1-mo 9.45%
3-mo 9.08%
6-mo 10.19%
1-year -52.74%
3-year N/A
5-year N/A
YTD -1.47%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.6691 seconds.